AstraZeneca has reported a significant boost in sales for the first half of 2026, driven primarily by strong demand for its cancer and rare disease treatments, even as the pharmaceutical giant increased its investment in new research.
The Cambridge-based firm saw total revenues climb 6% at constant exchange rates to $30.67 billion (£22.99 billion).